Vol. 9, Issue 4, Part C (2024)

The present study was carried out to examine the impact of the herbal hepato stimulant (GenoLiv) on Holstein Friesian crossbred cows. Fifteen postpartum cows were allocated into three distinct groups, i.e. control, T₁, and T₂ groups, based on milk production. The study included a control group of low-yielding cows fed a basal diet. In contrast, treatment groups T₁ and T₂ consisted of higher-yielding cows that received the same basal diet supplemented with the herbal hepato stimulant (GenoLiv) at dosages of 50 g/animal/day and 100 g/animal/day, respectively, over a period of three months. Serum samples were collected from each cow prior to the start of the trial and at monthly intervals to assess liver health. Serum biochemical parameters measured included serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), total bilirubin, and triglyceride levels. Daily milk yields and associated quality parameters, including fat percentage, milk fat yield, and solids-not-fat (SNF) content, were measured before the commencement of trial and at monthly intervals.

Results showed that GenoLiv supplementation in groups T₁ and T₂ significantly (p<0.001) reduced serum SGOT level, which was initially higher in these groups. However, there were no significant effects on the serum SGPT, bilirubin, triglycerides levels of cow supplementation with GenoLiv. The T₁ group had the highest average milk yield (liters/day) (p<0.001), followed by T₂, with the control group yielding the least.

The findings suggested that supplementation of GenoLiv to HF crossbred cows normalized previously impaired liver enzyme levels, and sustained milk production at the animals genetic potential.